Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for BCX17725 in Netherton syndrome. The expected timing is based on the latest available company guidance and may change.
10/02/24- Initiated enrollment. 8/4/25- Initial data by YE 2025. 11/03/25:- Phase 1 trial enrolling; initial patient data now expected by end of Q1 2026. 02/26/26:- Phase 1 Netherton trial now dosing; data in up to 12 patients expected by end of 2026. 05/06/26:- Began dosing Part 4 of Phase 1 Netherton trial; up to 12 patients, data expected by end 2026. 08/05/26:- Part 4 dosing continues; up to 12-patient data expected by end 2026.
Verification
Confirm timing and program details against the company announcement or filing.